



EVI Rendez-Vous
3rd December 2014
Auditorium Jacob - Institut Pasteur
28, rue Dr Roux - 75015 Paris

08:30	Registration	EVI crew
09:00	Welcome	Christian Bréchet
09:10	Organisation Remarks	Odile Leroy
09:20	EVI portfolio	Alister Craig

Preclinical Activities – Ashley Birkett and Giuseppe del Giudice

09:30	Combining cellular and humoral immune responses as a vaccine strategy against <i>Staphylococcus aureus</i> pathogen	Alexandre Le Vert (BELLEROPHON)
09:50	Universal flu vaccine based of diversity covering approach: antigen selection and production	Paula Alves (EDUFLUVAC)
10:10	<i>Coffee Break</i>	
10:40	VAR2CSA antigen: production and clinical development	Thor Theander (PAMCPH/PlacMalVac)
11:00	Process development	Hervé Ginisty (PRIMALVAC)
11:20	Rh5 – update	Simon Draper (InnoMalVac)

11:40	<i>Group picture</i>	
11:50	<i>Lunch break</i>	

Clinical Activities – Vasee Moorthy and Ingileif Jonsdottir

13:00	Preliminary results of a phase I/IIb clinical trial with ChAd63 ME-TRAP and MVA ME-TRAP	Alfred Tiono (MVVC)
13:20	Phase I/IIb safety and immunogenicity of ChAd63/MVA ME-TRAP vaccine candidates co-administered with EPI vaccines in infants	Muhammed Afolabi (MVVC 2)
13:40	Development of a multi-component multistage malaria vaccine – here we are	Adrian Hill (MultiMalVax)
14:00	AMA1-DiCo clinical trial phase Ia/Ib update	Duet Odile Launay and Adama Gansané (AMA1-DiCo)
14:40	Helminths and malaria	Akim Ayola (IDEA)
15:00	<i>Coffee Break</i>	
15:30	P27A clinical trial phase Ia/Ib update	Duet François Spertini and Seif Shekalaghe (P27A)
16:10	Standardisation and development of assays for assessment of influenza vaccine correlate of protection	Emanuele Montomoli (FLUCOP)
16:30	Development of a paratyphoid human infection model to accelerate vaccine development	Iain Milligan and Malick Gibani (PIM)
16:50	<i>Closing remarks</i>	<i>Alister Craig</i>

Today's Catalyst For Tomorrow's Vaccines